Akeso Biopharma Partners with Virogin to Test Ivonescimab and VG201 in Colorectal Cancer Trial
CompanyDeals

Akeso Biopharma Partners with Virogin to Test Ivonescimab and VG201 in Colorectal Cancer Trial

Berry Genomics Collaborates with Beijing Children’s Hospital on Newborn Birth Defects Screening Project
CompanyDeals

Berry Genomics Collaborates with Beijing Children’s Hospital on Newborn Birth Defects Screening Project

Trump Orders HHS to Reduce Drug Prices, Revamp Medicare Negotiation Program
Policy / Regulatory

Trump Orders HHS to Reduce Drug Prices, Revamp Medicare Negotiation Program

Galderma Launches Sculptra in China as First Regenerative Biostimulator
CompanyDrug

Galderma Launches Sculptra in China as First Regenerative Biostimulator

Easton Pharma's EP-9001A Shows Promising Results in Phase Ib for Bone Metastasis Cancer Pain
CompanyDrug

Easton Pharma’s EP-9001A Shows Promising Results in Phase Ib for Bone Metastasis Cancer Pain

Edwards Lifesciences Gains EU CE Mark for SAPIEN M3 Mitral Valve System
CompanyMedical Device

Edwards Lifesciences Gains EU CE Mark for SAPIEN M3 Mitral Valve System

InnoCare Pharma's Zurletrectinib NDA Accepted by China's CDE for TRK Fusion Cancers
CompanyDrug

InnoCare Pharma’s Zurletrectinib NDA Accepted by China’s CDE for TRK Fusion Cancers

NHC Releases Standardized Family Doctor Service Packages for Key Demographic Groups
Policy / Regulatory

NHC Releases Standardized Family Doctor Service Packages for Key Demographic Groups

Kosell Medtech Partners with Wenzhou Medical University on K-Sheath System
CompanyDeals

Kosell Medtech Partners with Wenzhou Medical University on K-Sheath System

Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies
CompanyDrug

Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies

Hansoh Pharmaceutical Gains Clinical Approval for KRAS G12D Targeted Drug HS-10529
CompanyDrug

Hansoh Pharmaceutical Gains Clinical Approval for KRAS G12D Targeted Drug HS-10529

AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients
CompanyDrug

AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients